STSA-1002 + STSA-1005

STSA-1002 + STSA-1005 is a combination of two monoclonal antibodies developed as an immunomodulatory therapy targeting excessive immune activation in severe and critical COVID-19 and acute respiratory distress syndrome. STSA-1002 is a human monoclonal antibody that inhibits C5a, a key mediator in complement-driven inflammation, aiming to reduce neutrophil recruitment and cytokine release in acute respiratory injury. STSA-1005 is a monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor (CSF-2R), functioning as an antagonist to further limit inflammatory responses. The drug combination is intended to maximize anti-inflammatory effects and prevent thrombosis complications by simultaneously inhibiting complement activation and GM-CSF signaling. Both agents are developed by Staidson and have been tested together in Phase 1 clinical studies for safety, tolerability, pharmacokinetics, and pharmacodynamics, primarily in healthy volunteers and targeting critical respiratory diseases including COVID-19 and ARDS[1][2][3][5][6][7][9].